---
title: KDM5B predicts temozolomide-resistant subclones in glioblastoma
date: '2024-01-04'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38174322/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240104170743&v=2.18.0
source: heidelberg[Affiliation]
description: Adaptive plasticity to the standard chemotherapeutic temozolomide (TMZ)
  leads to glioblastoma progression. Here, we examine early stages of this process
  in patient-derived cellular models, exposing the human lysine-specific demethylase
  5B (KDM5B) as a prospective indicator for subclonal expansion. By integration of
  a reporter, we show its preferential activity in rare, stem-like ALDH1A1+ cells,
  immediately increasing expression upon TMZ exposure. Naive, genetically unmodified
  KDM5B^(high) ...
disable_comments: true
---
Adaptive plasticity to the standard chemotherapeutic temozolomide (TMZ) leads to glioblastoma progression. Here, we examine early stages of this process in patient-derived cellular models, exposing the human lysine-specific demethylase 5B (KDM5B) as a prospective indicator for subclonal expansion. By integration of a reporter, we show its preferential activity in rare, stem-like ALDH1A1+ cells, immediately increasing expression upon TMZ exposure. Naive, genetically unmodified KDM5B^(high) ...